Treatment | Fold Increase Relative to Control | ||
---|---|---|---|
CYP2B1 mRNA | CYP3A23 mRNA | ||
Kaempferol-3-O-rutinoside | 0.5 ± 0.1 | 0.5 ± 0.2 | |
Quercetin-3-O-rutinoside | 1.1 ± 0.3 | 0.9 ± 0.1 | |
Isorhamnetin-3-O-rutinoside | 0.7 ± 0.2 | 0.7 ± 0.2 | |
Kaempferol | 0.9 ± 0.1 | 0.9 ± 0.1 | |
Quercetin | 1.6 ± 0.4 | 1.3 ± 0.2 | |
Isorhamnetin | 0.9 ± 0.1 | 0.9 ± 0.2 | |
Ginkgo biloba extract | 8.3 ± 1.7* | 5.3 ± 0.3* |
↵* Significantly different from the corresponding vehicle-treated control group (P < 0.05).